Inogen (INGN) PT Raised to $51 at Needham & Company

Needham & Company analyst Mike Matson reiterated a Strong Buy rating and boosted his price target on Inogen, Inc (NASDAQ: INGN) to $51.00 (from $47.00) following meetings with management.

Matson commented, "We hosted meetings with INGN management this week that reinforced our positive view of INGN. We expect portable oxygen concentrators (POCs) to become the standard of care and expect this to benefit INGN regardless of the sales channel. We expect INGN's international business to continue to exceed expectations. And we expect INGN's new G4 to drive a strong product cycle in 2016. We raise our price target to $51 and reiterate our Strong Buy rating."

For an analyst ratings summary and ratings history on Inogen, Inc click here. For more ratings news on Inogen, Inc click here.

Shares of Inogen, Inc closed at $44.48 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Upgrades Analog Devices (ADI) to Outperform
• Avita Medical Ltd. (RCEL) PT Raised to $14 at TD Cowen
• Centrus Energy Corp. (LEU) PT Raised to $185 at UBS